

## Drug and Therapeutics Committee – Minutes –Approved

<b>Date / Time</b>	Thursday 13 <sup>th</sup> April 2017
<b>Venue</b>	The Board Room, Alderson House, HRI
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	Mrs Susan Greene, Senior Pharmacy Technician (SG) Wendy Hornsby Pharmacy Technician
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG) Mr P O'Brien, Deputy Chief Pharmacist Dr A Sampson, Infectious Diseases Consultant Dr H Klonin, Consultant Paediatrician Mr K McCorry, Medicines Management, East Riding Dr O Ogunbambi, Consultant Rheumatologist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Prof M Lind, Vice Chair, Professor of Oncology Dr F Umerah, Consultant Anaesthetist
-------------------	---

<b>Apologies</b>	None
------------------	------

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2017.04.01	<b>Apologies</b>	None.					
2017.04.02	<b>Declarations of Interest</b>	None.					
2017.04.03	<b>Minutes of the previous meeting</b>	Dr Kapur to be changed to Mr Kapur, otherwise the minutes were accepted as a true record.					04/17
2017.04.04	<b>Action Tracker</b>	<p><b>Fluticasone furoate and Vilanterol (Revlar Ellipta)</b> POB to discuss and clarify commissioning DOT with respiratory service manager – ongoing.</p> <p><b>Stalevo &amp; generics</b> AM had received a letter from Dr Ming agreeing that patients can be switched over to generic brand but pointing out that this should be a once only switch and that patients should then stay on this brand. The committee agreed that HEY would continue with the Sastravi product and that AM would write to Dr Ming and thank him for his input. To be discussed further at MMIG.</p> <p><b>Bisphosphonates as supportive therapy for Breast Cancer</b> Once Leeds replied, ML would write a local protocol - to be sent to HERPC for further discussion.</p> <p><b>New Product Requests</b> Nicardipine - AM has written to applicant &amp; health group directors.</p> <p><b>NICE Guidance – February 2017</b> SG had amended the formulary for apremilast.</p> <p><b>Minutes from HERPC – 25/01/2017</b> <u>Paediatric Growth Hormone</u> DC had followed up re the commissioning by escalating the matter to the Trust Commissioning Department and to Dr Chris Wood, Clinical Director for Paediatrics. DC confirmed that around the</p>	<p>Commissioning requires clarification.</p> <p>Dr Ming to be thanked for input.</p> <p>Discuss at MMIG</p> <p>ML to write protocol and send to SG.</p> <p>Action Complete.</p> <p>Action Complete.</p> <p>Action Complete.</p>	<p>POB to ask service manager</p> <p>AM to write to Dr Ming</p> <p>SG to agenda</p> <p>Ongoing – Dr Dhadda is preparing</p>	<p>POB</p> <p>AM</p> <p>SG</p> <p>ML</p>	<p>6/17</p> <p>5/17</p> <p>5/17</p> <p>5/17</p>	<p>4/17</p> <p>4/17</p> <p>4/17</p>

		<p>Yorkshire region other Trusts operate with shared care, as is current local practice. SG will add to HERPC agenda.</p> <p>DC to invite Dr Wood to attend HERPC to discuss further. AM to put forward HEY D&amp;T's view at HERPC, which is that Paediatric growth hormone should be a shared care medicine.</p> <p><b>HEY Guideline to Medication Review In Falls</b> SPG has informed MM of the need for an author, reference to where the information comes from, preparation date and review dates to be added.</p> <p><b>Epclusa (Sofosbuvir and Velpatasvir)</b> The application had been circulated, as below - 2017.04.05.</p> <p><b>Issues to escalate to OQC</b> The nicardipine application had been included in the escalation report to OQC, as requested.</p>	<p>Discuss further at HERPC Dr Wood to be invited to speak at HERPC.</p> <p>Action Complete.</p> <p>Action Complete.</p> <p>Action Complete.</p>	<p>SG to agenda for HERPC DC to invite Dr Wood</p>	<p>SG</p> <p>DC</p>	<p>5/17</p> <p>5/17</p>	<p>4/17</p> <p>4/17</p> <p>4/17</p>
2017.04.05	<b>New Product Requests</b>	<p><b>Alteplase (Actilyse Cathflo) 2mg injection - Dr M Barraclough</b> Approved as a 2<sup>nd</sup> line agent after urokinase.</p> <p><b>Epclusa (Sofosbuvir and Velpatavir) - L Cullen</b> Approved in line with NHSE commissioning position.</p>	<p>Approved.</p> <p>Approved.</p>	<p>AM to write to applicant SG to update formulary</p>	<p>AM/SG</p>	<p>5/17</p>	
2017.04.06	<b>Stalevo &amp; Generics – Patient information for branded to generic switch overs.</b>	<p>The committee discussed the issues around switching patients onto different brands of Stalevo/Sastravi/Staneek. This included how to alert patients to the switch and if GP's would be responsible for switch, or whether it should occur in hospital. When HEY moved from Stalevo to Sastravi it was thought of as a normal generic switch that was unlikely to cause any issues, as we do with other drugs. In contrast, as the Trust introduces biosimilars there has been a well-planned process of informing patients, to minimise problems. <u>Post meeting note</u>: the Pharmacy information leaflet that is supplied with each patient's discharge medication already contains the line "The medicines dispensed by your local pharmacy MAY look different from those supplied by the hospital pharmacy". The committee agreed that further discussion should take place at MMIG.</p>	<p>POB, as lead for purchasing, would be mindful of the issues raised and aim to prevent future similar problems.</p> <p>Discuss further at MMIG.</p>	<p>SG to add to MMIG agenda</p>	<p>SG</p>	<p>5/17</p>	

2017.04.07	<b>NICE Guidance</b>	<p><b>NICE Guidance March 2017</b></p> <p>Mental health of adults in contact with the criminal justice system <a href="https://www.nice.org.uk/guidance/ng66">https://www.nice.org.uk/guidance/ng66</a></p> <p>Managing medicines for adults receiving social care in the community <a href="https://www.nice.org.uk/guidance/ng67">https://www.nice.org.uk/guidance/ng67</a></p> <p>Elotuzumab for previously treated multiple myeloma (terminated appraisal) <a href="https://www.nice.org.uk/guidance/ta434">https://www.nice.org.uk/guidance/ta434</a></p> <p>Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) <a href="https://www.nice.org.uk/guidance/ta435">https://www.nice.org.uk/guidance/ta435</a></p> <p>Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) <a href="https://www.nice.org.uk/guidance/ta436">https://www.nice.org.uk/guidance/ta436</a></p> <p>Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) <a href="https://www.nice.org.uk/guidance/ta437">https://www.nice.org.uk/guidance/ta437</a></p> <p>Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) <a href="https://www.nice.org.uk/guidance/ta438">https://www.nice.org.uk/guidance/ta438</a></p> <p>Cetuximab and panitumumab for previously untreated metastatic colorectal cancer <a href="https://www.nice.org.uk/guidance/ta439">https://www.nice.org.uk/guidance/ta439</a></p> <p>Ustekinumab for treating active psoriatic arthritis (updated) <a href="https://www.nice.org.uk/guidance/ta340">https://www.nice.org.uk/guidance/ta340</a></p>	Noted.	No further action		4/17
			Noted – for community.	No further action		4/17
			Noted.	No further action		4/17
			Noted.	No further action		4/17
			Noted.	No further action		4/17
			Noted.	No further action		4/17
			Noted.	No further action		4/17
			Panitumumab on CDF list - so will require new product request.	ML to arrange for new product request	ML	5/17
			Need to amend formulary to Dermatology & Rheumatology as per NICE TA180 & TA340.	SG to update formulary	SG	5/17

		<p>Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (update)  <a href="https://www.nice.org.uk/guidance/cg164">https://www.nice.org.uk/guidance/cg164</a></p> <p>Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)  <a href="https://www.nice.org.uk/guidance/ta240">https://www.nice.org.uk/guidance/ta240</a></p> <p>Ustekinumab for the treatment of adults with moderate to severe psoriasis (update)  <a href="https://www.nice.org.uk/guidance/ta180">https://www.nice.org.uk/guidance/ta180</a></p> <p>Early and locally advanced breast cancer: diagnosis and treatment (update)  <a href="https://www.nice.org.uk/guidance/cg80">https://www.nice.org.uk/guidance/cg80</a></p> <p>Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (update)  <a href="https://www.nice.org.uk/guidance/cg68">https://www.nice.org.uk/guidance/cg68</a></p>	<p>Noted, all 3 drugs are formulary.</p> <p>Noted.</p> <p>Noted – as above.</p> <p>Noted, not about drugs.</p> <p>Noted, no drug changes.</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p>			<p>4/17</p> <p>4/17</p> <p>4/17</p> <p>4/17</p> <p>4/17</p>
2017.04.08	<b>MHRA DSU – March 2017</b>	Launch of pilot reporting scheme for harms associated with illicit drugs – this should be discussed at the Medicine HG Governance meeting, for awareness with the teams in A&E and AMU.	To be raised at Medicine HG Governance meeting.	SPG to ask Marie Miller to raise at meeting	SPG	5/17	
2017.04.09	<b>SMPC Minutes – January 2017</b>	<p>Key points:</p> <ul style="list-style-type: none"> <li>• Diamorphine nasal spray has now been approved for use.</li> <li>• Patient Safety Alert – Insulin cartridges - potential change back to vials being discussed.</li> <li>• Open systems for injectable medicines - practice in trust being audited.</li> <li>• DC informed committee that safe havens for prescribing will be discussed at next meeting.</li> </ul>	Noted.	No further action			4/17
2017.04.10	<b>HERPC Minutes – January 2017</b>	The contents were noted.	Noted.	No further action			4/17
2017.04.11	<b>Correspondence Received</b>	<b>Clinical Guideline for Phenytoin Loading &amp; Maintenance Doses</b> The document has been updated in line with Patient Safety Alert (Nov/16) and the change in the BNF loading dose to 18-20mg/kg.	Pharmacy representative to attend new Trust	DC to arrange attendance	DC	5/17	

		<p>The document is on trust intranet but the committee raised the issue that documents are not always easy to find. DC will check who is on Trust new intranet committee and will arrange for a Pharmacy representative to attend.</p> <p><b>Ivermectin cream (Soolantra) flow chart</b> A 3<sup>rd</sup> revised treatment flow chart has been received in response to the committee's request. Unfortunately, it was felt that it still placed too much emphasis on ivermectin use. AM to feed back that oral preparations should be added to the severe arm of the flow chart, in line with NICE CKS (which is the source referenced on the document).</p> <p>SG to add to HERPC agenda.</p>	<p>intranet committee</p> <p>AM to feed back to Dr Zaman that flow chart is still not suitable.</p> <p>Discuss at HERPC</p>	<p>AM to write to Dr Zaman</p> <p>SG to agenda for HERPC</p>	<p>AM</p> <p>SG</p>	<p>5/17</p> <p>5/17</p>	
2017.04.12	<b>Chairs Approvals</b>	None.					4/17
2017.04.13	<b>Issues to Escalate to Operational Quality Committee</b>	None.					4/17
2017.04.14	<b>Any Other Business</b>	None.					4/17
2017.04.15	<b>Date and Time of Next Meeting</b>	<p><b>Date – Thursday 11<sup>th</sup> May 2017</b> <b>Time – 8.15am-9.30am</b> <b>Venue – Board Room, Alderson House, HRI</b></p>					